We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

POC Blood Test Analyzer Performs CBC in Five Minutes

By LabMedica International staff writers
Posted on 23 May 2022
Print article
Image: HemoScreen POC blood test analyzer makes testing simple and accessible anywhere (Photo courtesy of PixCell Medical)
Image: HemoScreen POC blood test analyzer makes testing simple and accessible anywhere (Photo courtesy of PixCell Medical)

The world's first and only lab-quality, portable plug-and-play Complete Blood Count (CBC) analyzer allows real-time blood testing to be performed by anyone, anywhere, providing critical health data on the spot. This facilitates fast diagnostic results and data-driven disease management decisions.

PixCell Medical Technologies, Ltd.’s (Yokne'am Illit, Israel) HemoScreen hematology analyzer is the only 5-part differential CBC analyzer that is FDA-cleared, CE-marked and TGA-approved for point-of-care use offers clinically proven lab-accurate readings of 20 standard blood count parameters within five minutes, with just one finger-prick of blood. PixCell's HemoScreen delivers lab-accurate diagnostic information that alloes healthcare professionals to make rapid and clinically reliable decisions supported by real-time data.

The portable point of care hematology analyzer combines flow cytometry and digital imaging in a single platform for CBC and WBC 5-part differential. HemoScreen employs a patented, disposable cartridge preloaded with all necessary reagents. This reduces reagent waste and eliminates the need for maintenance and calibration, providing CBC results as well as comprehensive abnormal cell flagging for earlier detection of infection and certain cancer types.

“PixCell has transformed routine blood testing by combining novel microfluidics, machine learning and AI into a point-of-care instrument that anyone can operate,” said Dr. Avishay Bransky, co-founder and CEO of PixCell Medical. “Our breakthrough technology is allowing lab-grade testing to become independent from central laboratories and highly skilled experts, putting data in the hands of the medical staff who need it most, when they need it and where they need it.”

Related Links:
PixCell Medical Technologies, Ltd. 

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
POC Test Reader
Microbial Infections In-Vitro Diagnostic Solution
Weezion dx
Gold Supplier
Automated Chemiluminescent Analyzer
QUANTA Flash M2 (MIT3)

Print article


Molecular Diagnostics

view channel
Image: A new method reliably detects protein changes in blood that are typical of Parkinson`s disease (Photo courtesy of Pexels)

First-Ever Blood Test Detects Parkinson’s Disease

Until now, the diagnosis of Parkinson's disease has been based primarily on typical movement disorders such as muscle stiffness, slower movements and shaking. However, the disease starts up to 20 years... Read more


view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.